NPIPL2 Activators
Epidermal growth factor, which, by binding to its specific receptor, triggers a cascade resulting in the translocation of transcription factors that can elevate gene expression, potentially influencing the likes of NPIPL2. Phorbol esters such as PMA tap into the PKC pathway, a conduit for modulating protein phosphorylation and altering cellular responses. Ionomycin, weaving its effects by increasing intracellular calcium, invokes a symphony of calmodulin-dependent kinases, while insulin, through its receptor, instigates the PI3K/Akt pathway, a pivotal axis in cellular signaling that could also affect NPIPL2's state of activity.
Adrenergic agonists like isoproterenol elevate cAMP, which in turn activates PKA, setting off a chain of phosphorylation events with the potential to sway NPIPL2's function. The interplay of kinase inhibitors such as U0126, PD98059, and LY294002 with their respective targets-the MEK and PI3K pathways-adds another layer to the regulatory network, influencing various proteins, possibly including NPIPL2. The role of db-cAMP as a mimic of cAMP further emphasizes the importance of PKA in these regulatory processes. Inhibitors like wortmannin and staurosporine broaden the spectrum of influence by targeting key kinases and altering phosphorylation landscapes. KN-93's specific inhibition of CaMKII underscores the nuanced control exerted by calcium signaling on protein activity
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA is a diacylglycerol analog that activates protein kinase C (PKC), which can phosphorylate target proteins and may influence NPIPL2 activity. | ||||||
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $78.00 $270.00 | 80 | |
Ionomycin is a calcium ionophore that elevates intracellular calcium levels, activating calmodulin-dependent pathways which may alter NPIPL2 function. | ||||||
Insulin | 11061-68-0 | sc-29062 sc-29062A sc-29062B | 100 mg 1 g 10 g | $156.00 $1248.00 $12508.00 | 82 | |
Insulin initiates a signaling pathway that activates PI3K/Akt, promoting glucose uptake and possibly affecting NPIPL2 through downstream signaling events. | ||||||
Isoproterenol Hydrochloride | 51-30-9 | sc-202188 sc-202188A | 100 mg 500 mg | $28.00 $38.00 | 5 | |
As a beta-adrenergic agonist, Isoproterenol increases cAMP levels, potentially impacting PKA activity and thereby modulating NPIPL2. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is an inhibitor of MEK, which is part of the MAPK/ERK pathway; by inhibiting MEK, it might indirectly influence NPIPL2 activity by altering the pathway's output. | ||||||
Dibutyryl-cAMP | 16980-89-5 | sc-201567 sc-201567A sc-201567B sc-201567C | 20 mg 100 mg 500 mg 10 g | $47.00 $136.00 $492.00 $4552.00 | 74 | |
db-cAMP is a cell-permeable cAMP analog that activates PKA and can lead to changes in phosphorylation patterns, potentially affecting NPIPL2. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor that, by altering PI3K/Akt pathway signaling, can indirectly modulate NPIPL2 activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
As an inhibitor of the MEK/ERK pathway, PD98059 may change the phosphorylation status of various proteins and transcription factors, which could indirectly affect NPIPL2. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is another PI3K inhibitor that can lead to changes in the PI3K/Akt pathway, potentially influencing NPIPL2. | ||||||
KN-93 | 139298-40-1 | sc-202199 | 1 mg | $182.00 | 25 | |
KN-93 is a selective inhibitor of Ca2+/calmodulin-dependent protein kinase II (CaMKII); its inhibition can alter calcium signaling pathways and may indirectly modify NPIPL2 activity. | ||||||